Illumina company Verinata Health published additional peer-reviewed data showing that Verinata’s non-invasive verifi prenatal test correctly detects aneuploidies across all test samples, even for patients with very low fetal fractions. The publication also documented that fetal fractions are different for pregnancies where the fetus has Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and other aneuploidies analyzed by the verifi prenatal test.